Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Thinking out loud

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Sep 26, 2022 4:31pm

168 Views

Post# 34987676

RE:Thinking out loud

AllinATE - trials are supposed to start by 28th - not sure when they'd news release the first enrollment.

Could release information on the study this week - OR - do they do a combo news release ?

IBD update ... by my estimate ... late in the year. A 352 update could come before the IBD update ... or again ... could they package a 352/IBD update together ? Hard to tell.

So many unknowns - hard to guesstimate.

<< Previous

Bullboard Posts

Next >>

How to decrease sector risk by owning hundreds of mineral assets